Evidence map›Paper›PMID 41591906›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.

Ariana N Jacobs, Dominique Jahn, Tim Beringer, Sebastian Wolf, Ramesh K Krishnan, Michael Engelke, Björn Häupl, Silvia Münch, Niklas Dienstbier, Martine Pape and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ariana N Jacobs *Department of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.
Dominique Jahn *Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main 60590, Germany.
Tim BeringerDepartment of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.
Sebastian WolfDepartment of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.
Ramesh K KrishnanFrankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main 60590, Germany.
Michael EngelkeInstitute for Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen 37075, Germany.
Björn HäuplFrankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main 60590, Germany.
Silvia MünchDepartment of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.
Niklas DienstbierDepartment of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.
Martine PapeDepartment of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.
Marion BodachFrankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main 60590, Germany.
Xin YuLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Nazli SerinDepartment of Hematology, Oncology and Tumor Immunology, Charité University Medical Center, Berlin 12203, Germany.
Rebecca Wurm-KuczeraDepartment of Hematology, Oncology and Tumor Immunology, Charité University Medical Center, Berlin 12203, Germany.
Alena ZindelFrankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main 60590, Germany.
Carmen DöbeleFrankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main 60590, Germany.
Björn ChapuyDepartment of Hematology, Oncology and Tumor Immunology, Charité University Medical Center, Berlin 12203, Germany.
Louis M StaudtLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Sebastian ScheichDepartment of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.
Thomas OellerichDepartment of Medicine 2, Hematology/Oncology, University Medical Center Frankfurt, Goethe University, Frankfurt am Main 60590, Germany.

Funding

Deutsche Forschungsgemeinschaft (DFG) 455784452 and 548257578Else Kröner-Fresenius-Stiftung (EKFS) 2024_EKEA.43LOEWE Hessen LOEWE/2/17/519/03/10.001(0004)/111
6 · The paper itself

Abstract

Diffuse large B cell lymphoma (DLBCL) is characterized by a variety of specific genetic alterations that impact signaling pathway dependencies and therapeutic outcomes. Among the recurrently mutated genes, we identified

Indexed as

Lymphoma, Large B-Cell, DiffuseReceptors, Antigen, B-CellrhoA GTP-Binding ProteinSignal TransductionActinsAnimalsCell Line, TumorEndocytosisHumansMutationNF-kappa BActinsNF-kappa BReceptors, Antigen, B-CellrhoA GTP-Binding ProteinRHOA protein, humanB cell receptorcytoskeletonDLBCLlymphomaRHOA

Identifiers

PMID41591906
PMCPMC12867627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.